In addition, such overexpression showed to have a remarkable decrease in the expression of some ABC transporters (ABCG2, ABCC1 and ABCB1), and finally reversing the imatinib resistance in CML cells. Here, ABCG2 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.